MedTrace Logo

Evaluation of Oral THC and CBD in Men and Women

NCT05067387 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

Conditions

  • Drug Abuse
  • Intoxication by Drug
  • Impairment

Interventions

DRUG

CBD

Oral CBD (20 mg)

DRUG

THC + CBD

Oral THC (20 mg) + CBD (20 mg)

DRUG

Placebo

Oral placebo

DRUG

THC

Oral THC (20 mg)

Sponsors & Collaborators

Principal Investigators

  • Ziva Cooper · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2027-06-15
Completion
2028-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067387 on ClinicalTrials.gov